This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Trobalt (EU), Retigabine (EU), D-23129, ezogabine
BioMedTracker has separate drug profiles for ezogabine and ezogabine extended release (XR). Please also see Ezogabine XR.
The primary mechanism of action of retigabine is the enhanced activation of heteromeric potassium channels composed of the KCNQ2 and KCNQ3 subunits. Retigabine can also increase synthesis of the inhibitory neurotransmitter-aminobutyric acid GABA.
Wyeth and Asta Medica
In 1999, Wyeth licensed the rights to retigabine from Asta Medica.
Xcel and Viatris
In February 2004, Xcel Pharmaceuticals acquired exclusive worldwide product rights to retigabine from Viatris (formerly Asta Medica). Xcel will have complete responsibility for worldwide clinical development, regulatory approval and commercialization rights. Deal terms were not disclosed.
Valeant and Xcel
In February 2005, Valeant Pharmaceuticals International announced that it signed a definitive agreement to acquire Xcel Pharmaceuticals.
Meda and Viatris
In August 2005, Meda AB acquired Viatris.
Valeant and GSK
In August 2008, Valeant Pharmaceuticals and GlaxoSmithKline (GSK) entered into an exclusive worldwide collaboration agreement for retigabine for the treatment of adult epilepsy patients with refractory partial onset seizures. Under the terms of the agreement, Valeant will grant GSK worldwide development and...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc. Mylan Inc.
Additional information available to subscribers only: